<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777296</url>
  </required_header>
  <id_info>
    <org_study_id>TR02-105</org_study_id>
    <nct_id>NCT00777296</nct_id>
  </id_info>
  <brief_title>Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)</brief_title>
  <official_title>Phase 2a Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) In Cystic Fibrosis Patients With Chronic Infections Due To Pseudomonas Aeruginosa.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insmed Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insmed Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A major factor in the respiratory health of cystic fibrosis (CF) subjects is acquisition of
      chronic Pseudomonas aeruginosa infections. The infection rate with P. aeruginosa increases
      with age and by age 18 years, 80% of CF subjects in the U.S. are infected. Liposomal Amikacin
      for Inhalation (Arikace™) is a sterile aqueous liposomal suspension consisting of amikacin
      sulfate encapsulated in liposomes. This formulation of amikacin maximizes the achievable dose
      and delivery to the lungs of subjects infected via a nebulizer. Because liposome particles
      are small enough to penetrate and diffuse through sputum into the bacterial biofilm, they
      deposit drug in close proximity to the bacterial colonies, thus improving the bioavailability
      of amikacin at the infection site. The clinically achievable doses of amikacin in the LAI
      formulation can effectively increase the half-life of the drug in the lungs, and decrease the
      potential for systemic toxicity. LAI offers several advantages over current therapies in
      treating CF subjects with chronic infection caused by P. aeruginosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis is a genetic disease resulting from mutations in a 230 kb gene on chromosome
      7 known as the cystic fibrosis transmembrane conductance regulator (CFTR). Study subjects
      with CF manifest pathological changes in a variety of organs that express CFTR. The lungs are
      frequently affected, the sequelae being chronic infections and airway inflammation. The
      principal goal of treatment of subjects with CF is to slow the chronic deterioration of lung
      function.

      This is a Phase 2a study of safety, and tolerability of 28 days of daily dosing of two dose
      (280 mg, and 560 mg) cohorts of Arikace™ versus placebo. Study subjects will be randomized to
      receive either study drug or placebo (1.5% NaCl) by inhalation via a PARI eFlow® nebulizer.
      Cohort 1 (280mg) will complete 28 days of daily dosing with Arikace™ and 14 day post dosing
      safety evaluation by the Safety Committee (DSMB) before initiation of enrollment in Cohort 2
      (560mg). Cohort 2 will complete 28 days of daily dosing, and a 14 day post dosing safety
      assessment by the DSMB to evaluate safety data. All study patients will be followed for
      safety, pharmacokinetics, clinical, and microbiologic activity for 28 days post completion of
      study treatment.

      The total study period will be up to 56 days, with screening visit occurring within the
      preceding 14 days prior to randomization. Patients will be clinically evaluated during the
      first 48 hours post-randomization, and weekly for the 28 days treatment period, and during
      the follow up visits at study days 35, 42, 49, and 56 days to determine safety, tolerability,
      pharmacokinetics (PK), and clinical, and microbiologic activity.

      Clinical laboratory parameters, audiology testing, clinical adverse events, and pulmonary
      function will be evaluated for all study subjects in order to determine the qualitative and
      quantitative safety and tolerability of Arikace™ compared to Placebo. Serum, urine, and
      sputum specimens will be collected at periodic intervals to assess PK. Additionally; sputum
      samples will be collected to determine changes in bacterial density. Pulmonary function
      testing and CFQ-R measurements will be assessed at selected time points throughout the study.

      DSMB has recommended the amendment of the main study to evaluate safety and efficacy of
      additional cycles of treatment with Arikace™. All patients who were randomized in the main
      study, were compliant with the study protocol, and continue meeting study eligibility
      criteria can be consented to participate in the open-label extension to evaluate the safety,
      tolerability and efficacy of 560 mg once daily dose of Arikace™ administered for six cycles
      over eighteen months. Each cycle will comprise of 28 days of treatment followed by 56 days
      off treatment. The total extension period will be up to 518 days (74 weeks, about 18 months).

      Clinical laboratory parameters, audiology testing, clinical adverse events, and pulmonary
      function will be evaluated for all study subjects in order to determine the longer term
      safety, tolerability, and efficacy of Arikace™. Serum specimens will be collected at periodic
      intervals to assess PK for safety. Additionally, sputum samples will be collected to
      determine changes in bacterial density. Pulmonary function testing and CFQ-R measurements
      will be assessed at selected time points throughout the study. Arikace™, Arikayce™, Liposomal
      Amikacin for Inhalation (LAI) and Amikacin Liposome Inhalation Suspension (ALIS) are all the
      same may be used interchangeably throughout the study and other studies evaluating amikacin
      liposome inhalation suspension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2007</start_date>
  <completion_date type="Actual">February 27, 2008</completion_date>
  <primary_completion_date type="Actual">February 27, 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Significant Laboratory Abnormalities.</measure>
    <time_frame>28 Days</time_frame>
    <description>Changes in chemistry and hematology lab tests (clinically significant value of CTCAE grade ≥ 3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Arikace™ in Serum.</measure>
    <time_frame>Day 1, Day 14 and Day 28</time_frame>
    <description>Measure PK parameters (AUC0-infinity) of Arikace™ in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) of Arikace in Serum (Cmax).</measure>
    <time_frame>Day 1, Day 14 and Day 28</time_frame>
    <description>Measure PK parameter (Cmax) of Arikace™ in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Arikace™ in Sputum (AUC).</measure>
    <time_frame>28 days</time_frame>
    <description>Measure PK parameter (AUC0-24) of Arikace™ in sputum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Arikace™ in Urine.</measure>
    <time_frame>Day 1, Day 14 and Day 28</time_frame>
    <description>Measure PK parameter (Ae0-24 (mg) of Arikace™.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Amikacin Levels of Arikace™.</measure>
    <time_frame>Day 1, Day 14 and Day 28</time_frame>
    <description>Measure PK parameter (sputum amicakin concentration) of Arikace™ in sputum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: FEV1 %-Predicted.</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Relative Change (%) from Baseline to End of treatment (Day 28) and Day 56 in Pulmonary Function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: FEV1.</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Mean Percent Change (%) from Baseline to End of treatment (Day 28) and Day 56 in Pulmonary Function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log10CFU Per Gram (Density) of Pseudomonas Aeruginosa in Sputum.</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28 and Day 35</time_frame>
    <description>End-of-treatment (Day 28) from baseline in density of P. aeruginosa (log10 CFU/g) in sputum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Systemic Antipseudomonal Rescue Therapy.</measure>
    <time_frame>Through study duration, approximately 56 days</time_frame>
    <description>Duration of systemic antipseudomonal rescue therapy during the study in both the ARIKACE™ and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Requiring Antipseudomonal Rescue Therapy.</measure>
    <time_frame>Through study duration, approximately 56 days</time_frame>
    <description>Number of Subjects requiring systemic antipseudomonal rescue therapy during the study in both the ARIKACE™ and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CFQ-R Respiratory Scale (Absolute Change From Baseline).</measure>
    <time_frame>Baseline/Day 1, Day 15, Day 28 and Day 42</time_frame>
    <description>Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - 280 mg ARIKACE™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this cohort will receive 280 mg of ARIKACE™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm of cohort 1 will receive matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - 560 mg ARIKACE™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this cohort will receive 560 mg of ARIKACE™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm of cohort 2 will receive matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARIKACE™</intervention_name>
    <description>Study start date is before Jan 18, 2017.</description>
    <arm_group_label>Cohort 1 - 280 mg ARIKACE™</arm_group_label>
    <arm_group_label>Cohort 2 - 560 mg ARIKACE™</arm_group_label>
    <other_name>liposomal amikacin for inhalation</other_name>
    <other_name>Arikayce</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study start date is before Jan 18, 2017.</description>
    <arm_group_label>Cohort 1 - Placebo</arm_group_label>
    <arm_group_label>Cohort 2 - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from patient or designated legal guardian prior to
             the performance of any study related procedures.

          -  Male or female study subjects ≥6 years of age or older

          -  Confirmed diagnosis of CF

          -  History of chronic infection with P. aeruginosa

          -  Study subjects must produce a screening specimen that is positive for growth of P.
             aeruginosa

          -  FEV1 ≥ 40% predicted at Screening

          -  SaO2 ≥ 90% at Screening while breathing room air

          -  Ability to comply with study medication use, study visits and study procedures as
             judged by the investigator

          -  Ability to produce sputum or be willing to undergo an induction to produce sputum for
             clinical evaluation

          -  Clinically stable with no evidence of acute upper or lower respiratory tract infection
             of history of pulmonary exacerbation within 4 weeks prior to screening

        Key Exclusion Criteria:

          -  Administration of any investigational drug within 8 weeks prior to Screening

          -  Emergency room visit or hospitalization for CF or respiratory-related illness within 4
             weeks prior to screening

          -  History of alcohol, medication or illicit drug abuse within the 1 year prior to
             screening

          -  History of lung transplant

          -  Female of childbearing potential who is lactating or is not practicing an acceptable
             method of birth control (e.g., abstinence, hormonal or barrier methods, partner
             sterilization, or IUD)

          -  Positive pregnancy test

          -  Use of any anti-pseudomonal anitbiotics (IV antibiotics, all inhalation antibiotics,
             oral fluoroquinolones)within the 28 days prior to screening

          -  Initiation of chronic therapy (i.e. TOBI®, high-dose ibuprofen, rhDNase, macrolide
             antibiotics) within 28 days prior to screening

          -  History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years
             of Screening

          -  History of mycobacterial or Aspergillus infection

          -  Requiring treatment within 2 years prior to screening, and/or history of allergic
             bronchopulmonary aspergillosis.

          -  History of biliary cirrhosis with portal hypertension, or splenomegaly

          -  History of daily, continuous oxygen supplementation or requirement for more than 2
             L/min at night Change in chest x-ray at screening (or within the 3 months prior to
             screening)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Eagle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Insmed Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skopje</city>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rabka-Zdrój</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>North Macedonia</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
  </removed_countries>
  <reference>
    <citation>Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, Young KR, Saiman L, Burns JL, Govan JR, Ramsey B, Gupta R; Arikace Study Group. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013 Sep;68(9):818-25. doi: 10.1136/thoraxjnl-2012-202230. Epub 2013 Jun 8.</citation>
    <PMID>23749840</PMID>
  </reference>
  <reference>
    <citation>Okusanya OO, Bhavnani SM, Hammel JP, Forrest A, Bulik CC, Ambrose PG, Gupta R. Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies. Antimicrob Agents Chemother. 2014 Sep;58(9):5005-15. doi: 10.1128/AAC.02421-13. Epub 2014 Mar 31.</citation>
    <PMID>24687506</PMID>
  </reference>
  <reference>
    <citation>Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008 Apr;61(4):859-68. doi: 10.1093/jac/dkn059. Epub 2008 Feb 27.</citation>
    <PMID>18305202</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <results_first_submitted>April 3, 2019</results_first_submitted>
  <results_first_submitted_qc>June 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2019</results_first_posted>
  <disposition_first_submitted>November 17, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>November 17, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 18, 2016</disposition_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Respiratory Infections</keyword>
  <keyword>Pulmonary Cystic Fibrosis</keyword>
  <keyword>CFTR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 - 280 mg ARIKACE™</title>
          <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 - Placebo</title>
          <description>Subjects in this arm of cohort 1 received matching placebo</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2 - 560 mg ARIKACE™</title>
          <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 - Placebo</title>
          <description>Subjects in this arm of cohort 2 received matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>CRF form not completed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 - 280 mg ARIKACE™</title>
          <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1 - Placebo</title>
          <description>Subjects in this arm of cohort 1 received matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2 - 560 mg ARIKACE™</title>
          <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2 - Placebo</title>
          <description>Subjects in this arm of cohort 2 received matching placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" spread="5.3"/>
                    <measurement group_id="B2" value="16.9" spread="7.9"/>
                    <measurement group_id="B3" value="16.6" spread="6.1"/>
                    <measurement group_id="B4" value="17.2" spread="5.8"/>
                    <measurement group_id="B5" value="16.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian (not of Hispanic origin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinically Significant Laboratory Abnormalities.</title>
        <description>Changes in chemistry and hematology lab tests (clinically significant value of CTCAE grade ≥ 3).</description>
        <time_frame>28 Days</time_frame>
        <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Placebo</title>
            <description>Subjects in this cohort who received placebo</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - 560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Placebo</title>
            <description>Subjects in this cohort received matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Laboratory Abnormalities.</title>
          <description>Changes in chemistry and hematology lab tests (clinically significant value of CTCAE grade ≥ 3).</description>
          <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophils absolute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes absolute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine clearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) of Arikace™ in Serum.</title>
        <description>Measure PK parameters (AUC0-infinity) of Arikace™ in serum.</description>
        <time_frame>Day 1, Day 14 and Day 28</time_frame>
        <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) of Arikace™ in Serum.</title>
          <description>Measure PK parameters (AUC0-infinity) of Arikace™ in serum.</description>
          <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
          <units>mg.hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" spread="3.40"/>
                    <measurement group_id="O2" value="7.92" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61" spread="4.04"/>
                    <measurement group_id="O2" value="12.5" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.03" spread="6.12"/>
                    <measurement group_id="O2" value="14.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) of Arikace in Serum (Cmax).</title>
        <description>Measure PK parameter (Cmax) of Arikace™ in serum.</description>
        <time_frame>Day 1, Day 14 and Day 28</time_frame>
        <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) of Arikace in Serum (Cmax).</title>
          <description>Measure PK parameter (Cmax) of Arikace™ in serum.</description>
          <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="0.58"/>
                    <measurement group_id="O2" value="1.08" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="1.02"/>
                    <measurement group_id="O2" value="1.84" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="1.45"/>
                    <measurement group_id="O2" value="2.27" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) of Arikace™ in Sputum (AUC).</title>
        <description>Measure PK parameter (AUC0-24) of Arikace™ in sputum.</description>
        <time_frame>28 days</time_frame>
        <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) of Arikace™ in Sputum (AUC).</title>
          <description>Measure PK parameter (AUC0-24) of Arikace™ in sputum.</description>
          <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
          <units>mcg*hr/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13120" spread="21386"/>
                    <measurement group_id="O2" value="22445" spread="18652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) of Arikace™ in Urine.</title>
        <description>Measure PK parameter (Ae0-24 (mg) of Arikace™.</description>
        <time_frame>Day 1, Day 14 and Day 28</time_frame>
        <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) of Arikace™ in Urine.</title>
          <description>Measure PK parameter (Ae0-24 (mg) of Arikace™.</description>
          <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="12.3"/>
                    <measurement group_id="O2" value="27.0" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="16.5"/>
                    <measurement group_id="O2" value="39.8" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="19.5"/>
                    <measurement group_id="O2" value="43.7" spread="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Amikacin Levels of Arikace™.</title>
        <description>Measure PK parameter (sputum amicakin concentration) of Arikace™ in sputum.</description>
        <time_frame>Day 1, Day 14 and Day 28</time_frame>
        <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Amikacin Levels of Arikace™.</title>
          <description>Measure PK parameter (sputum amicakin concentration) of Arikace™ in sputum.</description>
          <population>The PK population consisted of subjects who received amikacin, had at least one serum PK assessment and were not replaced.</population>
          <units>mcg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1197" spread="1.56"/>
                    <measurement group_id="O2" value="2395" spread="0.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1174" spread="1.01"/>
                    <measurement group_id="O2" value="3496" spread="0.973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1911" spread="1.28"/>
                    <measurement group_id="O2" value="2635" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function: FEV1 %-Predicted.</title>
        <description>Relative Change (%) from Baseline to End of treatment (Day 28) and Day 56 in Pulmonary Function.</description>
        <time_frame>Baseline, Day 28, and Day 56</time_frame>
        <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.
Placebo is a pooled value from cohort 280 mg and cohort 560 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
          <group group_id="O3">
            <title>Pooled Placebo</title>
            <description>Subjects in this arm received matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function: FEV1 %-Predicted.</title>
          <description>Relative Change (%) from Baseline to End of treatment (Day 28) and Day 56 in Pulmonary Function.</description>
          <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.
Placebo is a pooled value from cohort 280 mg and cohort 560 mg.</population>
          <units>Relative Percent (%) change in FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="20.0"/>
                    <measurement group_id="O2" value="62.9" spread="18.2"/>
                    <measurement group_id="O3" value="68.0" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="13.7"/>
                    <measurement group_id="O2" value="11.0" spread="16.4"/>
                    <measurement group_id="O3" value="0.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="8.8"/>
                    <measurement group_id="O2" value="13.8" spread="26.2"/>
                    <measurement group_id="O3" value="-3.8" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function: FEV1.</title>
        <description>Mean Percent Change (%) from Baseline to End of treatment (Day 28) and Day 56 in Pulmonary Function.</description>
        <time_frame>Baseline, Day 28, and Day 56</time_frame>
        <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.
Placebo is a pooled value from cohort 280 mg and cohort 560 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
          <group group_id="O3">
            <title>Pooled Placebo</title>
            <description>Subjects in this arm received matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function: FEV1.</title>
          <description>Mean Percent Change (%) from Baseline to End of treatment (Day 28) and Day 56 in Pulmonary Function.</description>
          <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.
Placebo is a pooled value from cohort 280 mg and cohort 560 mg.</population>
          <units>Mean Percent (%) Change in FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.022" spread="0.788"/>
                    <measurement group_id="O2" value="1.937" spread="0.936"/>
                    <measurement group_id="O3" value="1.968" spread="0.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="12.8"/>
                    <measurement group_id="O2" value="13.2" spread="16.2"/>
                    <measurement group_id="O3" value="2.2" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="8.6"/>
                    <measurement group_id="O2" value="13.2" spread="24.3"/>
                    <measurement group_id="O3" value="-4.4" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log10CFU Per Gram (Density) of Pseudomonas Aeruginosa in Sputum.</title>
        <description>End-of-treatment (Day 28) from baseline in density of P. aeruginosa (log10 CFU/g) in sputum.</description>
        <time_frame>Day 7, Day 14, Day 21, Day 28 and Day 35</time_frame>
        <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
          <group group_id="O3">
            <title>Pooled Placebo</title>
            <description>Subjects in this arm received matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log10CFU Per Gram (Density) of Pseudomonas Aeruginosa in Sputum.</title>
          <description>End-of-treatment (Day 28) from baseline in density of P. aeruginosa (log10 CFU/g) in sputum.</description>
          <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
          <units>log10CFU per gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" spread="1.882"/>
                    <measurement group_id="O2" value="-1.101" spread="2.170"/>
                    <measurement group_id="O3" value="0.052" spread="1.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.366" spread="2.013"/>
                    <measurement group_id="O2" value="-1.570" spread="2.161"/>
                    <measurement group_id="O3" value="-0.574" spread="1.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.044" spread="2.155"/>
                    <measurement group_id="O2" value="-2.283" spread="2.775"/>
                    <measurement group_id="O3" value="-0.440" spread="1.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.622" spread="1.881"/>
                    <measurement group_id="O2" value="-1.515" spread="1.699"/>
                    <measurement group_id="O3" value="-0.677" spread="1.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.380" spread="1.425"/>
                    <measurement group_id="O2" value="-1.313" spread="2.852"/>
                    <measurement group_id="O3" value="-0.445" spread="1.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Systemic Antipseudomonal Rescue Therapy.</title>
        <description>Duration of systemic antipseudomonal rescue therapy during the study in both the ARIKACE™ and placebo groups.</description>
        <time_frame>Through study duration, approximately 56 days</time_frame>
        <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>ARIKACE™ 280 mg</title>
            <description>Subjects who received the 280 mg dose of the ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>Placebo for ARIKACE™ 280 mg</title>
            <description>Subjects who received matching placebo for ARIKACE™ 280 mg dose.</description>
          </group>
          <group group_id="O3">
            <title>ARIKACE™ 560 mg</title>
            <description>Subjects who received the 560 mg dose of the ARIKACE™</description>
          </group>
          <group group_id="O4">
            <title>Placebo for ARIKACE™ 560 mg</title>
            <description>Subjects who received matching placebo for ARIKACE™ 560 mg dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Systemic Antipseudomonal Rescue Therapy.</title>
          <description>Duration of systemic antipseudomonal rescue therapy during the study in both the ARIKACE™ and placebo groups.</description>
          <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="0.00"/>
                    <measurement group_id="O2" value="27.00" spread="NA">Standard deviation does not apply because only 1 participant required rescue therapy</measurement>
                    <measurement group_id="O3" value="19.00" spread="NA">Standard deviation does not apply because only 1 participant required rescue therapy</measurement>
                    <measurement group_id="O4" value="21.00" spread="11.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Requiring Antipseudomonal Rescue Therapy.</title>
        <description>Number of Subjects requiring systemic antipseudomonal rescue therapy during the study in both the ARIKACE™ and placebo groups.</description>
        <time_frame>Through study duration, approximately 56 days</time_frame>
        <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>ARIKACE™</title>
            <description>Subjects who received either the 280 mg or the 560 mg doses of the ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects who received matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Requiring Antipseudomonal Rescue Therapy.</title>
          <description>Number of Subjects requiring systemic antipseudomonal rescue therapy during the study in both the ARIKACE™ and placebo groups.</description>
          <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CFQ-R Respiratory Scale (Absolute Change From Baseline).</title>
        <description>Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.</description>
        <time_frame>Baseline/Day 1, Day 15, Day 28 and Day 42</time_frame>
        <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 280 mg ARIKACE™</title>
            <description>Subjects in this cohort received 280 mg of ARIKACE™</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Placebo</title>
            <description>Subjects in this arm of cohort 1 received matching placebo</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - 560 mg ARIKACE™</title>
            <description>Subjects in this cohort received 560 mg of ARIKACE™</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Placebo</title>
            <description>Subjects in this arm of cohort 2 received matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>CFQ-R Respiratory Scale (Absolute Change From Baseline).</title>
          <description>Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.</description>
          <population>The analysis population is the modified intent-to-treat (mITT) population, defined as all randomized subjects who received at least one dose of study drug.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1/baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.619" spread="11.630"/>
                    <measurement group_id="O2" value="71.212" spread="14.921"/>
                    <measurement group_id="O3" value="67.989" spread="12.748"/>
                    <measurement group_id="O4" value="61.364" spread="21.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.632" spread="10.078"/>
                    <measurement group_id="O2" value="-0.505" spread="12.349"/>
                    <measurement group_id="O3" value="3.704" spread="16.133"/>
                    <measurement group_id="O4" value="-2.778" spread="16.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.306" spread="12.760"/>
                    <measurement group_id="O2" value="-3.283" spread="14.154"/>
                    <measurement group_id="O3" value="5.688" spread="11.669"/>
                    <measurement group_id="O4" value="1.667" spread="13.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.080" spread="12.169"/>
                    <measurement group_id="O2" value="-4.012" spread="19.598"/>
                    <measurement group_id="O3" value="3.042" spread="18.213"/>
                    <measurement group_id="O4" value="0.556" spread="12.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were assessed from the first dose (Visit 2) until the completion of the study follow-up (14 days after 28 days of dosing in cohort 2). The total duration is approximately 84 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 - 280 mg ARIKACE™</title>
          <description>Subjects in this cohort will receive 280 mg of ARIKACE™</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 - Placebo</title>
          <description>Subjects in this arm of cohort 1 will receive matching placebo</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2 - 560 mg ARIKACE™</title>
          <description>Subjects in this cohort will receive 560 mg of ARIKACE™</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 - Placebo</title>
          <description>Subjects in this arm of cohort 2 will receive matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ENTEROVIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EXACERBATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>APHTHOUS STOMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kevin Mange, Sr. Vice President, Clinical Development</name_or_title>
      <organization>Insmed Incorporated</organization>
      <phone>908-947-2651</phone>
      <email>Kevin.Mange@Insmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

